Average Co-Inventor Count = 6.53
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Regeneron Pharmaceuticals, Inc. (14 from 1,345 patents)
2. Regeneran Pharmaceuticals, Inc. (2 from 49 patents)
16 patents:
1. 12441800 - Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof
2. 12415856 - EGFR x CD28 multispecific antibodies
3. 12344677 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
4. 12077603 - Multispecific antigen-binding molecules for cell targeting and uses thereof
5. 12065508 - Multispecific antigen-binding molecules for cell targeting and uses thereof
6. 11952430 - Multispecific antigen-binding molecules for cell targeting and uses thereof
7. 11912767 - EGFR × CD28 multispecific antibodies
8. 11633501 - Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
9. 11548947 - Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof
10. 11485793 - Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
11. 11453721 - Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
12. 11155633 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
13. 10941208 - Anti-MUC16 antibodies
14. 10772972 - Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
15. 10738130 - Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof